The effects of omega-3 fatty acid supplementation upon interleukin-12 and interleukin-18 in chronic kidney disease patients

Kenneth Yong, Trevor Mori, Gerard Chew, Lawrence J. Beilin, Ian Puddey, Gerald F. Watts, Ashley Irish, Gursharan Dogra, Neil Boudville, Wai Lim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective(s): Cardiovascular disease (CVD) remains a leading cause of mortality in chronic kidney disease (CKD) patients. Interventions targeting traditional risk factors have largely proven ineffective in CKD patients in part because of the increased role of nontraditional risk factors such as chronic inflammation. Omega-3 fatty acids (ω3FA) are inexpensive and safe natural agents, which target inflammation and have potential cardioprotective benefits. The aim of the study was to determine the effects of ω3FA supplementation upon serum interleukin (IL)-12, IL-18, and highly sensitive C-reactive protein (hsCRP) in patients with Stage 3-4 CKD. Methods: We performed a post-hoc analysis of a randomized placebo-controlled trial in 73 nondiabetic CKD patients to determine the effects of ω3FA supplementation (4 g daily for 8 weeks) upon serum levels of IL-12, IL-18, and hsCRP. Results: There were no preintervention differences in IL-12, IL-18, or hsCRP between treatment groups. Postintervention levels of IL-12, IL-18, and hsCRP were similar between the treatment groups. However, IL-12 and IL-18 increased in both treatment groups over the intervention period, whereas hsCRP remained unchanged. The magnitude of increase in serum IL-18 (ΔIL-18) was significantly less in participants in the ω3FA treatment group compared to placebo (P =.047). Conclusion(s): This study has shown that 4 g daily ω3FA supplementation may lower serum IL-18 levels in patients with moderate CKD. Although there were no apparent effects on several other markers of inflammation, this study provides evidence for a specific effect of ω3FA on inflammatory pathways.

Original languageEnglish
Pages (from-to)377-385
Number of pages9
JournalJournal of Renal Nutrition
Volume29
Issue number5
Early online date2019
DOIs
Publication statusPublished - Sep 2019

Fingerprint

Interleukin-18
Omega-3 Fatty Acids
Interleukin-12
Chronic Renal Insufficiency
C-Reactive Protein
Fatty Acids
Inflammation
Serum
Placebos
Therapeutics
Cardiovascular Diseases
Randomized Controlled Trials
Mortality

Cite this

@article{e1b7fef3c5d642eea87a28a104c38ef4,
title = "The effects of omega-3 fatty acid supplementation upon interleukin-12 and interleukin-18 in chronic kidney disease patients",
abstract = "Objective(s): Cardiovascular disease (CVD) remains a leading cause of mortality in chronic kidney disease (CKD) patients. Interventions targeting traditional risk factors have largely proven ineffective in CKD patients in part because of the increased role of nontraditional risk factors such as chronic inflammation. Omega-3 fatty acids (ω3FA) are inexpensive and safe natural agents, which target inflammation and have potential cardioprotective benefits. The aim of the study was to determine the effects of ω3FA supplementation upon serum interleukin (IL)-12, IL-18, and highly sensitive C-reactive protein (hsCRP) in patients with Stage 3-4 CKD. Methods: We performed a post-hoc analysis of a randomized placebo-controlled trial in 73 nondiabetic CKD patients to determine the effects of ω3FA supplementation (4 g daily for 8 weeks) upon serum levels of IL-12, IL-18, and hsCRP. Results: There were no preintervention differences in IL-12, IL-18, or hsCRP between treatment groups. Postintervention levels of IL-12, IL-18, and hsCRP were similar between the treatment groups. However, IL-12 and IL-18 increased in both treatment groups over the intervention period, whereas hsCRP remained unchanged. The magnitude of increase in serum IL-18 (ΔIL-18) was significantly less in participants in the ω3FA treatment group compared to placebo (P =.047). Conclusion(s): This study has shown that 4 g daily ω3FA supplementation may lower serum IL-18 levels in patients with moderate CKD. Although there were no apparent effects on several other markers of inflammation, this study provides evidence for a specific effect of ω3FA on inflammatory pathways.",
author = "Kenneth Yong and Trevor Mori and Gerard Chew and Beilin, {Lawrence J.} and Ian Puddey and Watts, {Gerald F.} and Ashley Irish and Gursharan Dogra and Neil Boudville and Wai Lim",
year = "2019",
month = "9",
doi = "10.1053/j.jrn.2019.01.001",
language = "English",
volume = "29",
pages = "377--385",
journal = "Journal of Renal Nutrition",
issn = "1051-2276",
publisher = "W.B. Saunders Ltd",
number = "5",

}

The effects of omega-3 fatty acid supplementation upon interleukin-12 and interleukin-18 in chronic kidney disease patients. / Yong, Kenneth; Mori, Trevor; Chew, Gerard; Beilin, Lawrence J.; Puddey, Ian; Watts, Gerald F.; Irish, Ashley; Dogra, Gursharan; Boudville, Neil; Lim, Wai.

In: Journal of Renal Nutrition, Vol. 29, No. 5, 09.2019, p. 377-385.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effects of omega-3 fatty acid supplementation upon interleukin-12 and interleukin-18 in chronic kidney disease patients

AU - Yong, Kenneth

AU - Mori, Trevor

AU - Chew, Gerard

AU - Beilin, Lawrence J.

AU - Puddey, Ian

AU - Watts, Gerald F.

AU - Irish, Ashley

AU - Dogra, Gursharan

AU - Boudville, Neil

AU - Lim, Wai

PY - 2019/9

Y1 - 2019/9

N2 - Objective(s): Cardiovascular disease (CVD) remains a leading cause of mortality in chronic kidney disease (CKD) patients. Interventions targeting traditional risk factors have largely proven ineffective in CKD patients in part because of the increased role of nontraditional risk factors such as chronic inflammation. Omega-3 fatty acids (ω3FA) are inexpensive and safe natural agents, which target inflammation and have potential cardioprotective benefits. The aim of the study was to determine the effects of ω3FA supplementation upon serum interleukin (IL)-12, IL-18, and highly sensitive C-reactive protein (hsCRP) in patients with Stage 3-4 CKD. Methods: We performed a post-hoc analysis of a randomized placebo-controlled trial in 73 nondiabetic CKD patients to determine the effects of ω3FA supplementation (4 g daily for 8 weeks) upon serum levels of IL-12, IL-18, and hsCRP. Results: There were no preintervention differences in IL-12, IL-18, or hsCRP between treatment groups. Postintervention levels of IL-12, IL-18, and hsCRP were similar between the treatment groups. However, IL-12 and IL-18 increased in both treatment groups over the intervention period, whereas hsCRP remained unchanged. The magnitude of increase in serum IL-18 (ΔIL-18) was significantly less in participants in the ω3FA treatment group compared to placebo (P =.047). Conclusion(s): This study has shown that 4 g daily ω3FA supplementation may lower serum IL-18 levels in patients with moderate CKD. Although there were no apparent effects on several other markers of inflammation, this study provides evidence for a specific effect of ω3FA on inflammatory pathways.

AB - Objective(s): Cardiovascular disease (CVD) remains a leading cause of mortality in chronic kidney disease (CKD) patients. Interventions targeting traditional risk factors have largely proven ineffective in CKD patients in part because of the increased role of nontraditional risk factors such as chronic inflammation. Omega-3 fatty acids (ω3FA) are inexpensive and safe natural agents, which target inflammation and have potential cardioprotective benefits. The aim of the study was to determine the effects of ω3FA supplementation upon serum interleukin (IL)-12, IL-18, and highly sensitive C-reactive protein (hsCRP) in patients with Stage 3-4 CKD. Methods: We performed a post-hoc analysis of a randomized placebo-controlled trial in 73 nondiabetic CKD patients to determine the effects of ω3FA supplementation (4 g daily for 8 weeks) upon serum levels of IL-12, IL-18, and hsCRP. Results: There were no preintervention differences in IL-12, IL-18, or hsCRP between treatment groups. Postintervention levels of IL-12, IL-18, and hsCRP were similar between the treatment groups. However, IL-12 and IL-18 increased in both treatment groups over the intervention period, whereas hsCRP remained unchanged. The magnitude of increase in serum IL-18 (ΔIL-18) was significantly less in participants in the ω3FA treatment group compared to placebo (P =.047). Conclusion(s): This study has shown that 4 g daily ω3FA supplementation may lower serum IL-18 levels in patients with moderate CKD. Although there were no apparent effects on several other markers of inflammation, this study provides evidence for a specific effect of ω3FA on inflammatory pathways.

UR - http://www.scopus.com/inward/record.url?scp=85061834938&partnerID=8YFLogxK

U2 - 10.1053/j.jrn.2019.01.001

DO - 10.1053/j.jrn.2019.01.001

M3 - Article

VL - 29

SP - 377

EP - 385

JO - Journal of Renal Nutrition

JF - Journal of Renal Nutrition

SN - 1051-2276

IS - 5

ER -